Friedreich's Ataxia - Treatment Algorithm and Competitive Landscape 2017

  • ID: 4433445
  • Report
  • Region: Global
  • 158 Pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 5
Understand the Future Market Competition in the FRDA Market and Insightful Reviews of the Key Market Drivers and Barriers

FEATURED COMPANIES

  • Cardero Therapeutics
  • Chondrial Therapeutics
  • Edison Pharmaceuticals
  • others
  • Reata Pharmaceuticals
  • Retrotope
  • MORE

Friedreich’s ataxia is a rare inherited autosomal recessive disorder that causes nervous system damage and movement problems. It is caused by a mutation in a gene labeled frataxin (FXN). Over time this deficiency causes the aforementioned damage, as well as frequent fatigue due to effects on cellular metabolism. Friedreich’s ataxia is the most common of the autosomal recessive ataxias. Patients are prone to heart diseases like hypertrophic cardiomyopathy, which enlarges and weakens the heart muscle and can be life-threatening. Some affected individuals develop diabetes or an abnormal curvature of the spine.

According to the latest report Friedreich’s Ataxia - Treatment Algorithm and Competitive Landscape 2017, Friedreich ataxia (FRDA) is the most common inherited ataxia in Europe, the Middle East, South Asia (Indian subcontinent), and North Africa. It is estimated to affect 1 in 40,000 people in the United States.

Currently, there are more than 20 active pipeline products undergoing development in different clinical stages. Even at this stage there is no cure for this problem, available treatments are only focused on reducing the symptoms of disease effectively.

Some drugs that are currently in the pipeline Phase II includes RT001 (Retrotope), Epicatechin (Cardero Therapeutics), ABT-RTA 408 (Reata Pharmaceuticals), JOT101 (Jupiter Orphan Therapeutics), TAK-831 (Takeda), and Vatiquinone (Edison Pharmaceuticals). 3 drugs are in phase 1, 11 in preclinical and 3 in discovery phase. Currently, there are no drugs in the clinical phase III for the treatment of Friedreich’s Ataxia. There are several guidelines for the management and treatment of the disease provided by various US, Europe, and Australian clinicians. Europe - European Federation of neurological societies Guidelines, Australia - National Health and Medical Research Council (NHMRC) Australia, US - Friedreich’s Ataxia Research Alliance (FARA), Consensus Clinical Management Guidelines for Friedreich’s Ataxia.

The latest report has covered a detailed description of Diagnosis, Management and Treatment in Europe, US and Other Countries. Information about all the collaborations, financing and licensing deals. Complete Pipeline drugs profiling covering each and every phase of development. Not only pipeline drugs but the detailed description of the pre-clinical, discovery and inactive products is also provided in the report. Treatment algorithm and competitive is the main focus of this report making it a complete package for understanding the complete market scenario. Details about all the possible market drivers and barriers are also provided to better understand the areas of improvement and to plan the strategies accordingly.

Reasons to Buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the FRDA market.
  • To understand the future market competition in the FRDA market and insightful reviews of the key market drivers and barriers.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

This report may take up to 24 hours to be delivered

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cardero Therapeutics
  • Chondrial Therapeutics
  • Edison Pharmaceuticals
  • others
  • Reata Pharmaceuticals
  • Retrotope
  • MORE
  1. Friedreich’s Ataxia
  2. Disease Overview
  3. Cause
  4. Pathophysiology
  5. Pathogenesis
  6. Symptoms
  7. Diagnosis
  8. Treatment and Management
  9. Management of Friedreich’s Ataxia
  10. Diagnosis
  11. Clinical Diagnosis
  12. Genetic Diagnosis
  13. Genotype-phenotype correlation
  14. Genetic Testing
  15. International Guidelines for the clinical management of Friedreich’s ataxia and Treatment Algorithm
  16. United States
  17. Guidelines based on the different components of Friedreich ataxia
  18. Guidelines for treatment
  19. Guidelines in other countries
  20. Pipeline Therapeutics
  21. Comparative Analysis
  22. Mid Stage Products (Phase II)
  23. Comparative Analysis
  24. RT001: Retrotrope
  25. Product Description
  26. Research and development
  27. Product Development Activities
  28. Epicatechin: Cardero Therapeutics
  29. Product Description
  30. Research and development
  31. Vatiquinone: BioElectron
  32. Product Description
  33. Research and development
  34. Product Development Activities
  35. TAK-831: Takeda
  36. Product Description
  37. Research and Development
  38. And others
  39. Inactive Products
  40. Dormant Drugs
  41. Drivers and Barriers
  42. Appendix
  43. About

List of Tables
Table 1: Total Products for Friedreich’s Ataxia
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Preclinical and Discovery Stage Products
Table 5: Dormant Drugs
Table 6: Discontinued Drugs
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Stage and Molecule Type

List of Figures
Figure 1: Role of Mitochondria in Friedreich Ataxia Development
Figure 2: Mutation in Frataxin Gene
Figure 3: Iron-sulfur Cluster Synthesis during Pathophysiology of Friedreich’s Ataxia
Figure 4: Components based on FARA Clinical Management Guidelines
Figure 5: Neurological Component
Figure 6: The Heart, Cardiovascular and Respiratory System in Friedreich ataxia
Figure 7: Prevalence of obstructive sleep apnea (OSA) as FRDA progresses
Figure 8: Management of Pain
Figure 9: Scoliosis Management and Treatment
Figure 10: Diabeted Screening and Treatment
Figure 11: Genetic Issues Handling
Figure 12: European Federation of neurological societies Guidelines
Figure 13: Total Products for Friedreich’s Ataxia
Figure 14: Mid Stage Products (Phase II)
Figure 15: Early Stage Products (Phase I)
Figure 16: Preclinical and Discovery Stage Products
Figure 17: Dormant Drugs
Figure 18: Discontinued Drugs
Figure 19: Assessment by Monotherapy Products
Figure 20: Assessment by Route of Administration
Figure 21: Assessment by Molecule Type
Figure 22: Assessment by Stage and Route of Administration
Figure 23: Assessment by Stage and Molecule Type

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Cardero Therapeutics
  • Chondrial Therapeutics
  • Edison Pharmaceuticals
  • Jupiter Orphan Therapeutics
  • Reata Pharmaceuticals
  • Retrotope
  • Shire
  • Takeda
  • others
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll